Synthorx
La Jolla
About Synthorx
Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded by Avalon Ventures based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute in La Jolla, Calif. These discoveries include research published by the Romesberg lab in Nature, describing the first example of in vivo replication of a synthetic DNA base pair and the development of a semi-synthetic organism (read more here). Synthorx has the exclusive rights to this synthetic biology technology from The Scripps Research Institute. Investors include Avalon Ventures, Correlation Ventures, Medicxi, Orbimed, Osage University Partners, and RA Capital Management.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $100K – $500K
- Total funding: $76.1M
- Funding stage: M&A
- Last round: Series C (Apr 2018)
- Ticker: nasdaq:THOR
- Website: synthorx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Health Care, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/synthorx-143131 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.